Find any Australian or New Zealand company or fund (dead or alive) by using SEARCH above or go directly to the site:
|
|
07 November 2024
| Name: | ESENSE-LAB LTD (ESE) |
| ISIN: | AU000000ESE9 |
| Date of Listing: | 14 February 2017 |
| Date of Delisting: | 11 August 2021 |
Stock Exchange Status:
This entity was delisted from the Australian Securities Exchange on 11 August 2021.Legal Status:
ACN: 616 228 703
Registration Date: 01 December 2016
Capital Gains Tax (CGT) Status:
The securities in this entity, in our opinion, are of little or no value. We have made that assessment by reference to the circumstances leading to a suspension and/or delisting, the length of a suspension, share trading history and last on-market share price, most recent financial and cash flow statements, prospects (including likelihood of re-financing), and other factors including in particular whether the entity is in external administration. If you are seeking to crystallise a capital loss on your securities, that process can be easily and quickly initiated at our online Worthless Shares facility here: https://www.delisted.com.au/sell-worthless-and-other-securities/.
Updates, corrections, disagreements please email to admin@delisted.com.au
Further information: deListed and InvestoGain are operated by Investogain Pty Limited which is licensed by ASIC as an Australian Financial Services Licensee (AFSL 334036). deListed acquires only securities that it deems to be of little or no value, in circumstances where the holder is unable to sell their securities on-market in the normal manner. This service has been provided online via the company’s website www.delisted.com.au since 2004.
Getting advice: Information provided in this section is of a general nature and applicable only to Australian tax residents who hold their investments on capital account (ie for long-term investment purposes). It has been prepared without taking into account your financial needs or tax situation. Before acting on the information, deListed suggests that you consider whether it is appropriate for your circumstances and recommends that you seek independent legal, financial, or taxation advice.
Disclaimer: The information provided above is to the best of our knowledge accurate as of today. But you should bear in mind that it is of a general nature and does not constitute financial or tax advice. Investogain Pty Limited accepts no liability for any loss arising from reliance on this information, including reliance on information that is no longer current.
REGISTRY:
Link Market Services Perth
Level 12 QV1 Building 250 St Georges Terrace Perth WA 6000
Tel : +61 8 9211 6670 or 1300 554 474
Fax : +61 2 9287 0303
RegistryWebsite RegistryEmail
Shareholders in this company should consider crystallising a capital loss in 2024/25 by selling their shares. This process is now much easier and quicker. It can be achieved online by entering transaction details here. While, this usually makes good economic sense we recommend you seek professional advice before buying or selling securities, your accountant is probably the best person. | 10/07/2024 |
delisted at entity's request per Listing Rule 17.11 | 11/08/2021 |
we understand this company all but failed with its securities unquoted for more than a year - it has now determined that as an unlisted entity it would be better able to raise funds and avoid ongoing listing costs | 11/08/2021 |
The company lodges its Quarterly Activities/Appendix 4C Cash Flow Report. | 30/07/2021 |
The company releases a notice of proposed issue of securities - ESE. | 02/07/2021 |
The company's AGM will be held at Quest South Perth Foreshore, 22 Harper Terrace, South Perth, Western Australia, 6151 on Friday, 6 August 2021 at 1:30pm (Australian Western Standard Time). | 01/07/2021 |
The Company has formally applied to be removed from the official list under ASX Listing Rule 17.11. Following comprehensive consideration, the Board of the Company determined that the removal of the Company from the Official List is in the best interests of security holders. | 25/06/2021 |
The company releases a notification regarding unquoted securities - ESE. | 25/06/2021 |
The company releases a notification of cessation of securities - ESE. | 23/06/2021 |
2,000,000 Restricted Shares issued to a trustee and held on trust for former Chief Executive Officer, Mr Itzik Mizrahi (under his employment agreement), have been forfeited in accordance with the terms of their issue. 2,000,000 CDIs had inadvertently been issued over the Restricted Shares, and have been cancelled, and the underlying Restricted Shares have been returned to the Company to be held as dormant shares. | 21/06/2021 |
The company lodges its Quarterly Activities Report and Appendix 4C. | 30/04/2021 |
The company releases a Corporate Governance Statement and Appendix 4G. | 26/03/2021 |
The company lodges its Full Year Statutory Accounts. | 26/03/2021 |
The company lodges its Preliminary Final Report. | 01/03/2021 |
The company lodges its Quarterly Activities Report and Appendix 4C. | 29/01/2021 |
The company has entered into loan note agreements with a number of sophisticated and professional investors to raise $812,000 to meet operational expenditure and fund working capital requirements. The loan notes are unsecured and carry an interest rate of 12% per annum, which is payable in cash on the repayment date. Funds raised will be used to meet operational expenditure, costs of the offer, outstanding liabilities, and to provide working capital to progress the development of the company's sanitiser products. | 29/12/2020 |
The company releases an Investor Presentation. | 09/12/2020 |
Testing of eSense's two proprietary blend terpene profiles, TRP-ENV and TRP-COV, was undertaken to determine their anti-viral activity against HCoV-OC43 Corona strain virus in a range of formulas. HCoV-OC43 is a weak strain of human corona virus which represents an accepted surrogate to evaluate activity of substances against SARS-CoV-2. "¢ Results have shown that certain formulas containing eSense's proprietary terpene blends are effective at neutralising HCoV-OC43 viruses showing a significant log reduction in viral copy numbers with a neutralization efficiency at least as good as 70% ethanol. Based on the results, eSense-Lab plans to realise the Letter of Intent with SeaLaria, with the intention to commercialise an alcohol-free sanitiser comprising TRP-ENV and SeaLaria's red algae. | 27/11/2020 |
The company lodges its Quarterly Activities Report and Appendix 4C. | 03/11/2020 |
The company lodges its Appendix 4D and Half Year Accounts. | 01/09/2020 |
eSense has signed a research agreement with the Israeli Ministry of Health to commence a joint research project at the Central Virology lab located in the Chaim Sheba Medical Centre, the largest hospital in Israel, to test its proprietary TRP-ENVTM compound. The aim of the research project is to test TRP-ENV's efficacy against human coronavirusstrain termed OC43, that will be used as a model for SARS COV2, and will provide further research into terpenes' anti-viral qualities to reduce the ethanol content in sanitisers. Results will be relevant to previously announced projects with Wise Wine and SeaLaria. Tests will be conducted in stages with final results expected by November 2020. Approval for eSense to conduct these tests was granted by the MOH following several months of discussion with the Israeli central virologly lab of the MOH. | 31/08/2020 |
The company has become aware, following ASX queries, that it has not been in compliance with. In relation to Article 34 of the Articles of Association, the Company is pleased to confirm that the Company's joint company secretary, Mr Winton Willesee, has agreed to be appointed as an interim non-executive director of the Company, effective immediately. In relation to the Company not having the required number of "˜External Directors', the Companies Law requires the Company call a shareholders' meeting as soon as possible to appoint replacement External Directors. The Company intends to call a shareholders' meeting as soon as possible to consider the appointment of 2 new External Directors. ASX will require the Company's securities to remain in suspension until the conditions mentioned above are satisfied. The Company is also advancing its commercialisation efforts and accelerating the current business plan. | 31/07/2020 |
The company lodges its Quarterly Activities Report and Appendix 4C. | 31/07/2020 |
The securities of eSense-Lab Limited will be suspended from quotation immediately under Listing Rule 17.2, at the request of ESE, pending the release of an announcement regarding ASX's queries in relation to ESE's board composition and an announcement regarding a research agreement. | 27/07/2020 |
The suspension of trading in the securities of eSense-Lab Ltd will be lifted immediately following the release by ESE of an announcement regarding capital raising. | 14/04/2020 |
The company completes $1.145 million capital raising. $250,000 in Loan Notes issued to Sophisitcated Investors. Secures firm commitments from Sophisitcated Investors for a placement of securities to raise an additional $895,000 (conditional on shareholder approval). | 14/04/2020 |
The voluntary suspension is to last until the earlier of the company releasing an announcement regarding the capital raising or prior to commencement of trading on Tuesday, 14 April 2020. | 09/04/2020 |
The securities of eSense-Lab Ltd will be suspended from quotation immediately under Listing Rule 17.2, at the request of ESE, pending the release of an announcement regarding a capital raising. | 07/04/2020 |
The suspension of trading in the securities of eSense-Lab Ltd will be lifted from the commencement of trading on Thursday, 3 May 2018, following release of the Company's quarterly reports and receipt of satisfactory responses to ASX queries. | 02/05/2018 |
The company lodges its Quarterly Activities & Appendix 4C Cashflow Report. | 30/04/2018 |
The company releases its Appendix 4G and Corporate Governance Statement. | 04/04/2018 |
MMJ PhytoTech Limited notes that the shareholders of e-Sense Lab have not approved the issuance to MMJ of free options to acquire 1.25 million ordinary shares of e-Sense at $0.30 per share. Accordingly, under the terms of the placement of 2.5 million ordinary shares to MMJ by e-Sense in November 2017, e-Sense is to pay $199,000 to MMJ in consideration for those unapproved options. | 03/04/2018 |
The company releases the results of its AGM and EGM. | 03/04/2018 |
The company lodges its Full Year Statutory Accounts. | 29/03/2018 |
The company releases the Chairman's Address to Shareholders. | 29/03/2018 |
The company issues a response to ASX query. | 29/03/2018 |
The company issues a response to ASX Query. | 28/03/2018 |
The securities of eSense-Lab Limited will be suspended from official quotation immediately pursuant to Listing Rule 17.3. | 23/03/2018 |
listed entity carried for record purposes only | 14/02/2017 |
Shareholders in this company should consider crystallising a capital loss in 2024/25 by selling their shares. This process is now much easier and quicker. It can be achieved online by entering transaction details here. While, this usually makes good economic sense we recommend you seek professional advice before buying or selling securities, your accountant is probably the best person. | 10/07/2024 |
delisted at entity's request per Listing Rule 17.11 | 11/08/2021 |
we understand this company all but failed with its securities unquoted for more than a year - it has now determined that as an unlisted entity it would be better able to raise funds and avoid ongoing listing costs | 11/08/2021 |
The company lodges its Quarterly Activities/Appendix 4C Cash Flow Report. | 30/07/2021 |
The company releases a notice of proposed issue of securities - ESE. | 02/07/2021 |
The company's AGM will be held at Quest South Perth Foreshore, 22 Harper Terrace, South Perth, Western Australia, 6151 on Friday, 6 August 2021 at 1:30pm (Australian Western Standard Time). | 01/07/2021 |
The Company has formally applied to be removed from the official list under ASX Listing Rule 17.11. Following comprehensive consideration, the Board of the Company determined that the removal of the Company from the Official List is in the best interests of security holders. | 25/06/2021 |
The company releases a notification regarding unquoted securities - ESE. | 25/06/2021 |
The company releases a notification of cessation of securities - ESE. | 23/06/2021 |
2,000,000 Restricted Shares issued to a trustee and held on trust for former Chief Executive Officer, Mr Itzik Mizrahi (under his employment agreement), have been forfeited in accordance with the terms of their issue. 2,000,000 CDIs had inadvertently been issued over the Restricted Shares, and have been cancelled, and the underlying Restricted Shares have been returned to the Company to be held as dormant shares. | 21/06/2021 |
The company lodges its Quarterly Activities Report and Appendix 4C. | 30/04/2021 |
The company releases a Corporate Governance Statement and Appendix 4G. | 26/03/2021 |
The company lodges its Full Year Statutory Accounts. | 26/03/2021 |
The company lodges its Preliminary Final Report. | 01/03/2021 |
The company lodges its Quarterly Activities Report and Appendix 4C. | 29/01/2021 |
The company has entered into loan note agreements with a number of sophisticated and professional investors to raise $812,000 to meet operational expenditure and fund working capital requirements. The loan notes are unsecured and carry an interest rate of 12% per annum, which is payable in cash on the repayment date. Funds raised will be used to meet operational expenditure, costs of the offer, outstanding liabilities, and to provide working capital to progress the development of the company's sanitiser products. | 29/12/2020 |
The company releases an Investor Presentation. | 09/12/2020 |
Testing of eSense's two proprietary blend terpene profiles, TRP-ENV and TRP-COV, was undertaken to determine their anti-viral activity against HCoV-OC43 Corona strain virus in a range of formulas. HCoV-OC43 is a weak strain of human corona virus which represents an accepted surrogate to evaluate activity of substances against SARS-CoV-2. "¢ Results have shown that certain formulas containing eSense's proprietary terpene blends are effective at neutralising HCoV-OC43 viruses showing a significant log reduction in viral copy numbers with a neutralization efficiency at least as good as 70% ethanol. Based on the results, eSense-Lab plans to realise the Letter of Intent with SeaLaria, with the intention to commercialise an alcohol-free sanitiser comprising TRP-ENV and SeaLaria's red algae. | 27/11/2020 |
The company lodges its Quarterly Activities Report and Appendix 4C. | 03/11/2020 |
The company lodges its Appendix 4D and Half Year Accounts. | 01/09/2020 |
eSense has signed a research agreement with the Israeli Ministry of Health to commence a joint research project at the Central Virology lab located in the Chaim Sheba Medical Centre, the largest hospital in Israel, to test its proprietary TRP-ENVTM compound. The aim of the research project is to test TRP-ENV's efficacy against human coronavirusstrain termed OC43, that will be used as a model for SARS COV2, and will provide further research into terpenes' anti-viral qualities to reduce the ethanol content in sanitisers. Results will be relevant to previously announced projects with Wise Wine and SeaLaria. Tests will be conducted in stages with final results expected by November 2020. Approval for eSense to conduct these tests was granted by the MOH following several months of discussion with the Israeli central virologly lab of the MOH. | 31/08/2020 |
The company has become aware, following ASX queries, that it has not been in compliance with. In relation to Article 34 of the Articles of Association, the Company is pleased to confirm that the Company's joint company secretary, Mr Winton Willesee, has agreed to be appointed as an interim non-executive director of the Company, effective immediately. In relation to the Company not having the required number of "˜External Directors', the Companies Law requires the Company call a shareholders' meeting as soon as possible to appoint replacement External Directors. The Company intends to call a shareholders' meeting as soon as possible to consider the appointment of 2 new External Directors. ASX will require the Company's securities to remain in suspension until the conditions mentioned above are satisfied. The Company is also advancing its commercialisation efforts and accelerating the current business plan. | 31/07/2020 |
The company lodges its Quarterly Activities Report and Appendix 4C. | 31/07/2020 |
The securities of eSense-Lab Limited will be suspended from quotation immediately under Listing Rule 17.2, at the request of ESE, pending the release of an announcement regarding ASX's queries in relation to ESE's board composition and an announcement regarding a research agreement. | 27/07/2020 |
The suspension of trading in the securities of eSense-Lab Ltd will be lifted immediately following the release by ESE of an announcement regarding capital raising. | 14/04/2020 |
The company completes $1.145 million capital raising. $250,000 in Loan Notes issued to Sophisitcated Investors. Secures firm commitments from Sophisitcated Investors for a placement of securities to raise an additional $895,000 (conditional on shareholder approval). | 14/04/2020 |
The voluntary suspension is to last until the earlier of the company releasing an announcement regarding the capital raising or prior to commencement of trading on Tuesday, 14 April 2020. | 09/04/2020 |
The securities of eSense-Lab Ltd will be suspended from quotation immediately under Listing Rule 17.2, at the request of ESE, pending the release of an announcement regarding a capital raising. | 07/04/2020 |
The suspension of trading in the securities of eSense-Lab Ltd will be lifted from the commencement of trading on Thursday, 3 May 2018, following release of the Company's quarterly reports and receipt of satisfactory responses to ASX queries. | 02/05/2018 |
The company lodges its Quarterly Activities & Appendix 4C Cashflow Report. | 30/04/2018 |
The company releases its Appendix 4G and Corporate Governance Statement. | 04/04/2018 |
MMJ PhytoTech Limited notes that the shareholders of e-Sense Lab have not approved the issuance to MMJ of free options to acquire 1.25 million ordinary shares of e-Sense at $0.30 per share. Accordingly, under the terms of the placement of 2.5 million ordinary shares to MMJ by e-Sense in November 2017, e-Sense is to pay $199,000 to MMJ in consideration for those unapproved options. | 03/04/2018 |
The company releases the results of its AGM and EGM. | 03/04/2018 |
The company lodges its Full Year Statutory Accounts. | 29/03/2018 |
The company releases the Chairman's Address to Shareholders. | 29/03/2018 |
The company issues a response to ASX query. | 29/03/2018 |
The company issues a response to ASX Query. | 28/03/2018 |
The securities of eSense-Lab Limited will be suspended from official quotation immediately pursuant to Listing Rule 17.3. | 23/03/2018 |
listed entity carried for record purposes only | 14/02/2017 |
Your browser may reflect a date of printing in American format.
See steps here: https://www.delisted.com.au/sell-worthless-and-other-securities/ How do I sell it | 02/10/2021 21:24:46 |
What happens to our shares now you have delisted? | 25/08/2021 21:41:20 |
How do I sell ese | 23/08/2021 13:07:44 |
how can i sale my share if company delisted from ASX | 13/08/2021 17:03:57 |
| NAME | TITLE | DATE OF APPT |
|---|---|---|
| James Ellingford | Non Exec Chairman | 13/01/2020 |
| Yoav Elishoov | CEO | 07/12/2020 |
| Peter Hatfull | Non Exec Director | 02/07/2020 |
| Winton Willesee | Non Exec Director, Company Secretary | 31/07/2020 |
| Erlyn Dale | Company Secretary |
Date of first appointment, title may have changed.
| NAME | TITLE | DATE OF APPOINTMENT | DATE OF RESIGNATION |
|---|---|---|---|
| Itzik Mizrahi | CEO | 09/03/2020 | 07/12/2020 |
| Benjamin Karasik | Director | 09/02/2018 | 31/10/2020 |
| Piers Lewis | Non Exec Director | 30/11/2018 | 02/07/2020 |
| Amit Edr | Non Exec Director | 30/11/2018 | 09/06/2020 |
| Michael Edwards | Non Exec Director | 08/11/2019 | 27/03/2020 |
| Haim Cohen | Director | 01/10/2016 | 30/01/2020 |
| Galit Asaf | Non Exec Director | 05/12/2016 | 08/11/2019 |
| Kobi Zecharia | Non Exec Director | 30/05/2018 | 20/12/2018 |
| Ilan Saad | Chairman | 01/10/2016 | 11/05/2018 |
| Eran Gilboa | Non Exec Director | 19/09/2016 | 11/05/2018 |
| Quentin Megson | Non Exec Director | 05/12/2016 | 29/03/2018 |
| Brendan de Kauwe | Director | 01/10/2016 | 29/03/2018 |
Date of first appointment, title may have changed.
Contact Us | Financial Services Guide | Privacy Policy
This website is owned and operated by Investogain Pty Limited.
ABN 88 129 443 447 | AFSL 334036
Information provided is of a general nature and not for trading or advice.
Copyright © 2002-2024 Investogain Pty Limited. All rights reserved.
